Global Fund Core Contribution 2026-2028

The Global Fund is a proven model for scaling impact by combining local leadership with global expertise and gathering governments, communities, the private sector, and other key actors. Since 2002, it has saved 65 million lives, reducing mortality from HIV/AIDS, tuberculosis, and malaria by 61% in low- and middle-income countries.

With annual investments exceeding USD 5 billion, the Global Fund provides 28% of international funding for HIV/AIDS, 76% for tuberculosis and 62% for malaria. From 2002 to 2023, these investments generated an estimated USD 1.2 trillion in health benefits, USD 400 billion in productivity gains and USD 103 billion in healthcare savings.

Switzerland has played a key role in ensuring that the Global Fund adheres to international standards and is complementary with other global institutions. Switzerland has also participated in the governance performance assessment performed by an external entity. As an Alternate Board Member for the Canada-Switzerland-Australia constituency until July 2024, Switzerland has actively supported risk management, ethical conduct, and the prevention of and response to sexual exploitation, abuse and harassment.

Switzerland's financial contributions were bolstered by its expertise gained through bilateral programmes in health system strengthening, equity, health financing, malaria and HIV/AIDS. Through the BACKUP initiative, Switzerland has focused its support on the P4H Social Health Protection Network, assisting low- and middle-income countries in mobilizing and optimizing domestic health resources.

The achievement of the primary goal of the Global Fund Strategy 2023–28 relies on four key objectives:

1. Maximizing People-centered Integrated Systems for Health to Deliver Impact, Resilience and Sustainability.

2. Maximizing the Engagement and Leadership of Most Affected Communities to Leave No One Behind.

3. Maximizing Health Equity, Gender Equality and Human Rights.

4. Mobilizing Increased Resources, in a context of financial austerity, particularly in relation to the three diseases.

The strategy emphasizes the importance of improving pandemic preparedness and response based on the experience of the COVID-19 crisis.

Switzerland’s approach strategy to influence policy is in areas where it can offer added value:

1. Reinforce countries and communities, especially the highest burden/lowest income context, to regain and sustain progress in the fight against HIV, TB and malaria.

2. Ensure essential programmatic interventions, qualitative prioritization, transition planning and financial optimization.

3. Fostering greater alignment with other global health initiatives and efficiency by increasing clarity on roles and resources commitments and by reinforcing accountability.

4. Strengthened risk management, ethical behavior and governance for improved organizational effectiveness and efficiency.

17

Public sector (93%): USA, France, UK, Germany, Canada, European Commission, Sweden, Australia, Japan, Italy, NL, Norway, Spain, Denmark, Belgium, Ireland, Portugal, Russian Federation, Saudia Arabia, Republic of Korea, Switzerland.

Private donor and non-governmental (7%): Bill and Melinda Gates Foundation, Johnson & Johnson Foundation, etc.

At board level, Switzerland belongs to a constituency alongside Canada and Australia. Canada is the permanent Board Member, while Australia and Switzerland take turns to fill the Alternate Member seat. Switzerland will take over this function from Australia for the period from mid-2026 to mid-2028 and will be a member of the Ethics and Governance Committee from May 2025 to May 2028.

Phase 15 01.01.2026 - 31.12.2028   (Active)